This clinical trial is focused on studying a rare bleeding disorder called Glanzmann Thrombasthenia. This condition affects the blood’s ability to clot properly, leading to frequent and sometimes severe bleeding episodes. The trial will investigate a new treatment called HMB-001, which is administered as a solution for injection or infusion under the skin. The purpose of the study is to assess the safety and tolerability of HMB-001 and to explore its potential to reduce the frequency and severity of bleeding episodes in individuals with Glanzmann Thrombasthenia.

The study is divided into different parts. Initially, participants will receive single and multiple doses of HMB-001 to determine the safest and most effective dose levels. Following this, the study will continue with repeated doses to confirm the safety and tolerability of the treatment. Throughout the trial, researchers will monitor participants for any side effects and changes in their health, as well as measure the treatment’s impact on bleeding frequency and severity.

Participants will undergo regular health assessments, including physical exams and laboratory tests, to ensure their well-being during the study. The trial aims to provide valuable information on the potential benefits of HMB-001 for managing Glanzmann Thrombasthenia, with the hope of improving the quality of life for those affected by this condition.